Alaunos Therapeutics, Inc. — fact timeline

Alaunos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 9, 2026, Alaunos Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice states that the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, reported stockholders’ equity of $2,153,000. As of the date of the Notice”

Alaunos Therapeutics, Inc. issued common stock.

“On January 8, 2026, the Board of Directors of the Company approved and adopted Amended and Restated By-Laws of the Company (the “Amended and Restated Bylaws”), effective immediately.”

Alaunos Therapeutics, Inc. terminated Engagement Letter dated August 14, 2023 with Cantor Fitzgerald & Co. valued at Termination of engagement letter for strategic transactions advisory; no fees payable upon terminati (effective 2026-01-08).

“On January 8, 2026, the Company delivered written notice to Cantor Fitzgerald & Co. (“Cantor”) terminating, effective immediately, the engagement letter dated August 14, 2023 (the “Engagement Letter”), pursuant to which Cantor had been engaged as the Company’s exclusive financial advisor in connection with the exploration of potential strategic transactions.”

Alaunos Therapeutics, Inc. entered into Settlement and Release Agreement with The University of Texas M.D. Anderson Cancer Center valued at $285,055 (effective 2025-12-17).

“On December 17, 2025, Alaunos Therapeutics, Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with The University of Texas M.D. Anderson Cancer Center (“MD Anderson”) resolving all disputes related to unpaid invoices under the 2019 Research and Development Agreement.”

Robert Hofmeister resigned as director at Alaunos Therapeutics, Inc..

“Robert Hofmeister, Ph.D. Resignation On April 15, 2025, Dr. Hofmeister resigned as a member of the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) with immediate effect.”

Alaunos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 7, 2025, Alaunos Therapeutics, Inc., (the “Company”) received a notice (the “Notice”) from the Listing Qualifications staff of Nasdaq notifying the Company that the Company’s stockholders equity as reported in its Annual Report on Form 10-K for the period ended December 31, 2024 (the “2024 10-K”), did not satisfy the continued listing requirements under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholder equity be at least $2,500,000. In its 2024 10-K, the Company reported stockholders’ equity of $2,063,000, and, as a result, d”

Ferdinand Groenewald was appointed as Vice President, Finance at Alaunos Therapeutics, Inc..

“On February 22, 2024, the Company and Ferdinand Groenewald entered into a consulting agreement (the “Consulting Agreement”), effective February 22, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company’s Vice President, Finance.”

Michael Wong resigned as Vice President, Finance at Alaunos Therapeutics, Inc..

“On February 15, 2024, Michael Wong gave notice of his resignation as Vice President, Finance, of Alaunos Therapeutics, Inc. (the "Company"), effective February 23, 2024.”

Alaunos Therapeutics, Inc.: Filed a Second Amended and Restated Certificate of Incorporation to effect a 1-for-15 reverse stock split (effective 2024-01-31).

“On January 31, 2024, Alaunos Therapeutics, Inc. (the “Company”) filed a Second Amended and Restated Certificate of Incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company’s common stock at a ratio of 1-for-15 (the “Reverse Split”).”

Dale Curtis Hogue, Jr. was appointed as Interim Chief Executive Officer at Alaunos Therapeutics, Inc..

“On January 20, 2024, the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) appointed Dale Curtis Hogue, Jr. as Interim Chief Executive Officer of the Company, effective January 20, 2024.”

Dale Curtis Hogue, Jr. was appointed as director at Alaunos Therapeutics, Inc..

“On December 29, 2023, the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) appointed Dale Curtis Hogue, Jr. as a director of the Company, effective immediately.”

Kevin S. Boyle, Sr. resigned as Director at Alaunos Therapeutics, Inc..

“Pursuant to the terms of his employment agreement, upon his termination Mr. Boyle was deemed to automatically resign from the Company’s board of directors.”

Kevin S. Boyle, Sr. was terminated as Chief Executive Officer at Alaunos Therapeutics, Inc..

“On December 22, 2023, Alaunos Therapeutics, Inc. (the “Company”) entered into a Separation and Release Agreement, effective December 22, 2023, with Kevin S. Boyle, Sr. (the “Separation Agreement”), the Company’s Chief Executive Officer, in connection with Mr. Boyle’s termination.”

Mary Thistle resigned as member of the board of directors at Alaunos Therapeutics, Inc..

“On December 18, 2023, Mary Thistle resigned as a member of the board of directors of Alaunos Therapeutics, Inc. (the “Company”) with immediate effect.”

Melinda Lackey was terminated as Senior Vice President, Legal and Administration at Alaunos Therapeutics, Inc..

“the Company terminated the employment of Melinda Lackey, Senior Vice President, Legal and Administration”

Alaunos Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $8.5 million, or $(0.04) per share.

“On November 14, 2023, Alaunos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial condition and results of operations for the three months ended September 30, 2023.”

Alaunos Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(A)(iii)).

“November 8, 2023, the Company received a Staff Delisting Determination letter (the “Delisting Determination”) from the Staff notifying the Company that, because the closing bid price for the Common Stock was below $0.10 per share for 10 consecutive trading days during the Extended Compliance Period, the Staff has determined to suspend trading of the Common Stock on Nasdaq pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii), effective November 17, 2023, and file a Form 25-NSE with the Securities and Exchange Commission (the “SEC”) to remove the Common Stock from listing and registration under th”

Holger Weis was elected as Chairman at Alaunos Therapeutics, Inc..

“With Mr. Huang’s departure, the Board has elected Holger Weis as the Company’s new Chairman of the Board.”

James Huang resigned as Chairman at Alaunos Therapeutics, Inc..

“On September 22, 2023, James Huang resigned as Chairman and member of the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) with immediate effect in order to focus on other business pursuits.”

Alaunos Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $8.8 million, or $(0.04) per share, EPS $(0.04) per share.

“On August 14, 2023, Alaunos Therapeutics, Inc. (the “Company”) issued a press release announcing financial results for the three and six months ended June 30, 2023”

Alaunos Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“July 5, 2023, Nasdaq notified the Company that the Transfer was approved, and that, in connection with the Transfer, the Company was eligible for an additional 180 calendar day period, or until January 2, 2024 (the “Extended Compliance Date”), to regain compliance with the Bid Price Requirement. Effective at the opening of business on July 7, 2023, the Common Stock will be transferred to the Nasdaq Capital Market. The Common Stock will continue to trade under the symbol “TCRT.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Select Market, but with less”

Alaunos Therapeutics, Inc.: Increased authorized shares of common stock from 420,000,000 to 520,000,000 (effective 2023-06-12).

“the Company’s stockholders voted on and approved an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”) to increase the number of authorized shares of common stock from 420,000,000 shares to 520,000,000 shares.”

Alaunos Therapeutics, Inc. shareholders approved Adjournment proposal to permit further solicitation if needed for Proposals 5 and 6 at the 2023-06-06 meeting.

“For Against Abstain Broker Non-Votes 144,264,709 34,642,989 1,934,513 —”

Alaunos Therapeutics, Inc. shareholders approved Approval of amendment to Certificate of Incorporation to increase authorized shares of common stock from 420,000,000 to 520,000,000 at the 2023-06-06 meeting.

“Proposal 6 - Approval of Amendment of the Certificate of Incorporation”

Alaunos Therapeutics, Inc. shareholders approved Approval of amendment and restatement of Certificate of Incorporation to effect a reverse stock split at ratio between 1-for-5 and 1-for-15 at the 2023-06-06 meeting.

“For Against Abstain Broker Non-Votes 141,445,911 38,471,417 924,883 —”

Alaunos Therapeutics, Inc. shareholders voted on Advisory vote on frequency of say-on-pay votes at the 2023-06-06 meeting.

“One Year Two Years Three Years Abstain 94,445,383 776,719 3,126,416 10,474,602”

Alaunos Therapeutics, Inc. shareholders approved Advisory vote on executive compensation at the 2023-06-06 meeting.

“For Against Abstain Broker Non-Votes 85,893,572 20,980,848 1,948,700 72,019,091”

Alaunos Therapeutics, Inc. shareholders approved Ratification of RSM US LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-06 meeting.

“For Against Abstain Broker Non-Votes 165,357,175 14,209,546 1,275,490 —”

Alaunos Therapeutics, Inc. shareholders approved Election of Directors at the 2023-06-06 meeting.

“Proposal 1 - Election of Directors The Company’s stockholders elected all seven persons listed below as directors”

Alaunos Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $10.0 million, EPS $(0.04) per share.

“Net loss was $10.0 million, or $(0.04) per share, for the first quarter of 2023”

Alaunos Therapeutics, Inc. amended Amended and Restated Exclusive License Agreement with Precigen, Inc. valued at $75,000 (effective 2023-04-03).

“On April 3, 2023, Alaunos Therapeutics, Inc. (the “Company”) and Precigen, Inc. (“Precigen”) entered into the Amended and Restated Exclusive License Agreement (the “A&R Agreement”) which amended and restated in its entirety the original Exclusive License Agreement, dated October 5, 2018, as amended (the “Original Agreement”).”

Alaunos Therapeutics, Inc. amended Third Amendment with lenders party thereto and Silicon Valley Bank (SVB), a division of First-Citizens Bank & Trust Company (effective 2023-03-30).

“Third Amendment to the Loan and Security Agreement Effective March 30, 2023, Alaunos Therapeutics, Inc. (the “Company”), as borrower, entered into a Third Amendment (the “Amendment”) to the Loan and Security Agreement, dated August 6, 2021, as previously amended (the “Original Agreement” and, as amended by the Amendment, the “Amended Agreement”), by and among the Company, the lenders party thereto and Silicon Valley Bank (“SVB”), a division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to SVB)), as administrative agent and collateral agent.”

Robert Hofmeister was appointed as Director at Alaunos Therapeutics, Inc..

“the Board appointed Robert Hofmeister, Ph.D., as a director of the Company effective immediately.”

Christopher Bowden resigned as Director at Alaunos Therapeutics, Inc..

“Christopher Bowden, M.D. delivered notice of his resignation from the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”), effective March 30, 2023.”

Alaunos Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2022.

“On March 7, 2023, Alaunos Therapeutics, Inc. (the “Company”) issued a press release announcing its fourth quarter and full year 2022 financial results.”

Alaunos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“January 4, 2023, Alaunos Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(”

Alaunos Therapeutics, Inc. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at approximately $14.6 million (effective 2022-11-29).

“On November 29, 2022, Alaunos Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Underwriter”), as the sole underwriter, relating to the issuance and sale in an underwritten offering (the “Offering”) of 24,228,719 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share, to the Underwriter at a price of $0.6191 per share.”

Alaunos Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $2.9 million.

“Collaboration revenue was $2.9 million for the third quarter of 2022, compared to $0.4 million for the third quarter of 2021, an increase of 631%.”

Alaunos Therapeutics, Inc. reported three months ended March 31, 2022 results: net income Net loss was $9.8 million, or $(0.05) per share, EPS $(0.05) per share.

“Alaunos Therapeutics, Inc. issued a press release announcing its financial condition and results of operations for the three months ended March 31, 2022.”

Heidi Hagen resigned as member of the Board of Directors at Alaunos Therapeutics, Inc..

“Effective November 2, 2021, Ms. Heidi Hagen has resigned as member of the Board of Directors (“the Board”) of Ziopharm Oncology, Inc. (the “Company”).”

Kevin G. Lafond departed as Sr. Vice President Finance, Chief Accounting Officer and Treasurer at Alaunos Therapeutics, Inc..

“Kevin G. Lafond, Sr. Vice President Finance, Chief Accounting Officer and Treasurer, is separating from the Company effective November 8, 2021”

Heidi Hagen resigned as Interim Chief Executive Officer at Alaunos Therapeutics, Inc..

“Heidi Hagen, who has served as the Company’s Interim Chief Executive Officer since February 2021, will resign as the Company’s Chief Executive Officer.”

Kevin S. Boyle, Sr. was appointed as Chief Executive Officer and Director at Alaunos Therapeutics, Inc..

“On August 22, 2021, the board of directors, or the Board, of ZIOPHARM Oncology, Inc., or the Company, appointed Kevin S. Boyle, Sr., age 48, as Chief Executive Officer of the Company, effective August 30, 2021.”